Intangible Assets, Net	3 Months Ended
Mar. 31, 2021
Intangible Assets, Net
Intangible Assets, Net	6. Intangible Assets, Net As of March 31, 2021, the Company’s finite-lived intangible assets, which totaled $5.0 million, resulted from the capitalization of certain milestone payments made to Ipsen Pharma, S.A.S., or Ipsen, in accordance with the terms of the Company’s license agreement with Ipsen, in connection with the Company’s first commercial sale of IMCIVREE in the U.S. in March 2021. The Company began amortizing its finite-lived intangible assets in March 2021 over IMCIVREE’s initial regulatory exclusivity period. Amortization expense was not material for the three months ended March 31, 2021. Amortization expense will be included in cost of sales on the consolidated statements of operations and comprehensive loss.

Intangible Assets, Net

3 Months Ended

Mar. 31, 2021

6. Intangible Assets, Net

As of March 31, 2021, the Company’s finite-lived intangible assets, which totaled $5.0 million, resulted from the capitalization of certain milestone payments made to Ipsen Pharma, S.A.S., or Ipsen, in accordance with the terms of the Company’s license agreement with Ipsen, in connection with the Company’s first commercial sale of IMCIVREE in the U.S. in March 2021.

The Company began amortizing its finite-lived intangible assets in March 2021 over IMCIVREE’s initial regulatory exclusivity period. Amortization expense was not material for the three months ended March 31, 2021. Amortization expense will be included in cost of sales on the consolidated statements of operations and comprehensive loss.